Annual Revenue
$36.27 M
-$15.85 M-30.40%
31 December 2023
Summary:
Intellia Therapeutics annual revenue is currently $36.27 million, with the most recent change of -$15.85 million (-30.40%) on 31 December 2023. During the last 3 years, it has risen by +$3.22 million (+9.75%). NTLA annual revenue is now -37.45% below its all-time high of $57.99 million, reached on 31 December 2020.NTLA Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$9.11 M
+$2.15 M+30.96%
30 September 2024
Summary:
Intellia Therapeutics quarterly revenue is currently $9.11 million, with the most recent change of +$2.15 million (+30.96%) on 30 September 2024. Over the past year, it has increased by +$11.03 million (+575.27%). NTLA quarterly revenue is now -68.51% below its all-time high of $28.93 million, reached on 31 March 2024.NTLA Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$43.09 M
-$2.88 M-6.27%
30 September 2024
Summary:
Intellia Therapeutics TTM revenue is currently $43.09 million, with the most recent change of -$2.88 million (-6.27%) on 30 September 2024. Over the past year, it has increased by +$6.81 million (+18.78%). NTLA TTM revenue is now -30.88% below its all-time high of $62.34 million, reached on 30 September 2020.NTLA TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NTLA Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +575.3% | +18.8% |
| 3 y3 years | +9.8% | -29.1% | +30.4% |
| 5 y5 years | -15.8% | -16.7% | -0.0% |
NTLA Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -30.4% | +9.8% | -68.5% | +575.3% | -19.4% | +30.4% |
| 5 y | 5 years | -37.5% | +9.8% | -68.5% | +575.3% | -30.9% | +60.8% |
| alltime | all time | -37.5% | +500.2% | -68.5% | +575.3% | -30.9% | +3250.4% |
Intellia Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $9.11 M(+31.0%) | $43.09 M(-6.3%) |
| June 2024 | - | $6.96 M(-76.0%) | $45.97 M(-12.6%) |
| Mar 2024 | - | $28.93 M(-1609.4%) | $52.60 M(+45.0%) |
| Dec 2023 | $36.27 M(-30.4%) | -$1.92 M(-116.0%) | $36.27 M(-29.9%) |
| Sept 2023 | - | $11.99 M(-11.8%) | $51.77 M(-2.4%) |
| June 2023 | - | $13.59 M(+7.8%) | $53.04 M(-0.8%) |
| Mar 2023 | - | $12.61 M(-7.1%) | $53.48 M(+2.6%) |
| Dec 2022 | $52.12 M(+57.7%) | $13.57 M(+2.3%) | $52.12 M(+1.4%) |
| Sept 2022 | - | $13.27 M(-5.4%) | $51.40 M(+13.4%) |
| June 2022 | - | $14.03 M(+24.7%) | $45.34 M(+19.8%) |
| Mar 2022 | - | $11.25 M(-12.5%) | $37.86 M(+14.5%) |
| Dec 2021 | $33.05 M(-43.0%) | $12.85 M(+78.4%) | $33.05 M(+23.4%) |
| Sept 2021 | - | $7.20 M(+10.0%) | $26.79 M(-35.9%) |
| June 2021 | - | $6.55 M(+1.6%) | $41.81 M(-18.9%) |
| Mar 2021 | - | $6.45 M(-2.3%) | $51.52 M(-11.2%) |
| Dec 2020 | $57.99 M(+34.5%) | $6.59 M(-70.3%) | $57.99 M(-7.0%) |
| Sept 2020 | - | $22.22 M(+36.6%) | $62.34 M(+22.9%) |
| June 2020 | - | $16.26 M(+25.9%) | $50.73 M(+11.3%) |
| Mar 2020 | - | $12.92 M(+18.1%) | $45.59 M(+5.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $43.10 M(+41.6%) | $10.94 M(+3.0%) | $43.10 M(+7.6%) |
| Sept 2019 | - | $10.62 M(-4.5%) | $40.05 M(+8.7%) |
| June 2019 | - | $11.12 M(+6.6%) | $36.84 M(+10.3%) |
| Mar 2019 | - | $10.43 M(+32.4%) | $33.40 M(+9.7%) |
| Dec 2018 | $30.43 M(+16.5%) | $7.88 M(+6.4%) | $30.43 M(+4.1%) |
| Sept 2018 | - | $7.41 M(-3.5%) | $29.22 M(+0.3%) |
| June 2018 | - | $7.68 M(+2.8%) | $29.13 M(+6.4%) |
| Mar 2018 | - | $7.47 M(+12.0%) | $27.37 M(+4.8%) |
| Dec 2017 | $26.12 M(+58.5%) | $6.67 M(-8.9%) | $26.12 M(+4.2%) |
| Sept 2017 | - | $7.32 M(+23.7%) | $25.08 M(+10.8%) |
| June 2017 | - | $5.92 M(-4.8%) | $22.63 M(+8.2%) |
| Mar 2017 | - | $6.21 M(+10.4%) | $20.92 M(+26.9%) |
| Dec 2016 | $16.48 M(+172.7%) | $5.63 M(+15.6%) | $16.48 M(+31.4%) |
| Sept 2016 | - | $4.87 M(+15.8%) | $12.54 M(+34.0%) |
| June 2016 | - | $4.21 M(+136.7%) | $9.36 M(+43.3%) |
| Mar 2016 | - | $1.78 M(+5.0%) | $6.54 M(+8.1%) |
| Dec 2015 | $6.04 M | $1.69 M(+0.3%) | $6.04 M(+38.9%) |
| Sept 2015 | - | $1.69 M(+22.6%) | $4.35 M(+63.4%) |
| June 2015 | - | $1.38 M(+7.1%) | $2.66 M(+107.1%) |
| Mar 2015 | - | $1.29 M | $1.29 M |
FAQ
- What is Intellia Therapeutics annual revenue?
- What is the all time high annual revenue for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly revenue?
- What is the all time high quarterly revenue for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly revenue year-on-year change?
- What is Intellia Therapeutics TTM revenue?
- What is the all time high TTM revenue for Intellia Therapeutics?
- What is Intellia Therapeutics TTM revenue year-on-year change?
What is Intellia Therapeutics annual revenue?
The current annual revenue of NTLA is $36.27 M
What is the all time high annual revenue for Intellia Therapeutics?
Intellia Therapeutics all-time high annual revenue is $57.99 M
What is Intellia Therapeutics quarterly revenue?
The current quarterly revenue of NTLA is $9.11 M
What is the all time high quarterly revenue for Intellia Therapeutics?
Intellia Therapeutics all-time high quarterly revenue is $28.93 M
What is Intellia Therapeutics quarterly revenue year-on-year change?
Over the past year, NTLA quarterly revenue has changed by +$11.03 M (+575.27%)
What is Intellia Therapeutics TTM revenue?
The current TTM revenue of NTLA is $43.09 M
What is the all time high TTM revenue for Intellia Therapeutics?
Intellia Therapeutics all-time high TTM revenue is $62.34 M
What is Intellia Therapeutics TTM revenue year-on-year change?
Over the past year, NTLA TTM revenue has changed by +$6.81 M (+18.78%)